Adoptive cell transfer
Adoptive cell transfer is the passive transfer of cells, most commonly immune-derived cells, into a new recipient host with the goal of transferring the immunologic functionality and characteristics into the new host. Clinically, this approach has been exploited to transfer either immune-promoting or tolergenic cells (often lymphocytes) to patients to either enhance immunity against viruses and cancer[1] [2] [3] or to promote tolerance in the setting of autoimmune disease,[4] such as Type I diabetes or rheumatoid arthritis.
Uses
To treat cancer
The adoptive transfer of autologous tumor infiltrating lymphocytes (TIL)[5][6][7] or genetically re-directed peripheral blood mononuclear cells[8][9] has been used to successfully treat patients with advanced solid tumors, including melanoma and colorectal carcinoma, as well as patients with CD19-expressing hematologic malignancies.
To prevent and treat viral disease
To induce tolerance in autoimmune disease
e.g. Transfer regulatory T cells to treat Type 1 diabetes and others.[4]
References
- ^ Gattinoni L, Powell DJ, Rosenberg SA, Restifo NP (May 2006). "Adoptive immunotherapy for cancer: building on success". Nature Reviews Immunology 6 (5): 383–93. doi:10.1038/nri1842. PMC 1473162. PMID 16622476. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1473162.
- ^ June CH (June 2007). "Adoptive T cell therapy for cancer in the clinic". The Journal of Clinical Investigation 117 (6): 1466–76. doi:10.1172/JCI32446. PMC 1878537. PMID 17549249. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1878537.
- ^ Schmitt TM, Ragnarsson GB, Greenberg PD (October 2009). "T Cell Receptor Gene Therapy for Cancer". Human Gene Therapy 20 (11): 1240–8. doi:10.1089/hum.2009.146. PMC 2829456. PMID 19702439. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2829456.
- ^ a b Riley JL, June CH, Blazar BR (May 2009). "Human T Regulatory Cells as Therapeutic Agents: Take a Billion or So of These and Call Me in the Morning". Immunity 30 (5): 656–65. doi:10.1016/j.immuni.2009.04.006. PMC 2742482. PMID 19464988. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2742482.
- ^ Besser MJ, Shapira-Frommer R, Treves AJ, et al. (May 2010). "Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients". Clin. Cancer Res. 16 (9): 2646–55. doi:10.1158/1078-0432.CCR-10-0041. PMID 20406835
- ^ Dudley ME, Wunderlich JR, Robbins PF, et al. (October 2002). "Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes". Science 298 (5594): 850–4. doi:10.1126/science.1076514. PMC 1764179. PMID 12242449. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1764179.
- ^ Dudley ME, Wunderlich JR, Yang JC, et al. (April 2005). "Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma". Journal of Clinical Oncology 23 (10): 2346–57. doi:10.1200/JCO.2005.00.240. PMC 1475951. PMID 15800326. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1475951.
- ^ Johnson LA, Morgan RA, Dudley ME, et al. (July 2009). "Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen". Blood 114 (3): 535–46. doi:10.1182/blood-2009-03-211714. PMC 2929689. PMID 19451549. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2929689.
- ^ Morgan RA, Dudley ME, Wunderlich JR, et al. (October 2006). "Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes". Science 314 (5796): 126–9. doi:10.1126/science.1129003. PMC 2267026. PMID 16946036. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2267026.